Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RGLS
CUSIP75915K10
Phone858-202-6300
Debt
Debt-to-Equity RatioN/A
Current Ratio1.27
Quick Ratio1.27
Price-To-Earnings
Trailing P/E Ratio-0.22
Forward P/E Ratio-0.43
P/E GrowthN/A
Sales & Book Value
Annual Sales$70,000.00
Price / Sales313.05
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book0.62
Profitability
EPS (Most Recent Fiscal Year)($0.96)
Net Income$-71,900,000.00
Net Margins-83,538.89%
Return on Equity-205.48%
Return on Assets-85.96%
Miscellaneous
Employees63
Outstanding Shares104,800,000
Market Cap$21.91 million
Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions
What is Regulus Therapeutics' stock symbol?
Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."
How were Regulus Therapeutics' earnings last quarter?
Regulus Therapeutics Inc (NASDAQ:RGLS) issued its earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.16) by $0.02. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.02 million. Regulus Therapeutics had a negative return on equity of 205.48% and a negative net margin of 83,538.89%. View Regulus Therapeutics' Earnings History.
When is Regulus Therapeutics' next earnings date?
What price target have analysts set for RGLS?
7 Wall Street analysts have issued twelve-month price objectives for Regulus Therapeutics' stock. Their forecasts range from $0.50 to $2.00. On average, they anticipate Regulus Therapeutics' share price to reach $1.10 in the next twelve months. This suggests a possible upside of 426.1% from the stock's current price. View Analyst Price Targets for Regulus Therapeutics.
What is the consensus analysts' recommendation for Regulus Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regulus Therapeutics.
What are Wall Street analysts saying about Regulus Therapeutics stock?
Here are some recent quotes from research analysts about Regulus Therapeutics stock:
- 1. According to Zacks Investment Research, "Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. " (8/16/2018)
- 2. Wedbush analysts commented, "We believe this move will likely create some investor/analyst churn in the near term but will open up capital allocation and capacity to focus on the growing CHCA and CHCI segments in the longer term. Although the sale will likely take a couple quarters to complete, we believe this shift will attract a more consumer focused investor base lead to upside from the weak share performance following the report. As such, we remain BUY rated on PRGO shares." (8/10/2018)
Are investors shorting Regulus Therapeutics?
Regulus Therapeutics saw a decline in short interest in the month of August. As of August 31st, there was short interest totalling 469,101 shares, a decline of 48.1% from the August 15th total of 904,197 shares. Based on an average daily volume of 2,251,716 shares, the short-interest ratio is presently 0.2 days. Currently, 0.6% of the company's stock are short sold. View Regulus Therapeutics' Current Options Chain.
Who are some of Regulus Therapeutics' key competitors?
Some companies that are related to Regulus Therapeutics include Medicure (MCUJF), Trillium Therapeutics (TRIL), IntelGenx Technologies (IGXT), Fortress Biotech (FBIO), Alpine Immune Sciences (ALPN), Axsome Therapeutics (AXSM), Oramed Pharmaceuticals (ORMP), Ophthotech (OPHT), Pharmaxis (PXSLY), Otonomy (OTIC), IMMUTEP LTD/S (IMMP), Cardiome Pharma (CRME), Chiasma (CHMA), Sophiris Bio (SPHS) and Humanigen (HGEN).
Who are Regulus Therapeutics' key executives?
Regulus Therapeutics' management team includes the folowing people:
- Mr. Joseph P. Hagan, Pres, CEO & Director (Age 49)
- Mr. Daniel R. Chevallard, Chief Financial Officer (Age 38)
- Dr. Timothy Michael Wright, Chief R&D Officer (Age 62)
- Ms. Allison Wey, VP of Investor Relations & Corp. Communications
- Mr. Christopher Aker, VP of Legal Affairs & Corp. Sec.
How do I buy shares of Regulus Therapeutics?
Shares of RGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Regulus Therapeutics' stock price today?
One share of RGLS stock can currently be purchased for approximately $0.2091.
How big of a company is Regulus Therapeutics?
Regulus Therapeutics has a market capitalization of $21.91 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-71,900,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Regulus Therapeutics employs 63 workers across the globe.
What is Regulus Therapeutics' official website?
How can I contact Regulus Therapeutics?
Regulus Therapeutics' mailing address is 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-202-6300 or via email at [email protected]
MarketBeat Community Rating for Regulus Therapeutics (NASDAQ RGLS)
MarketBeat's community ratings are surveys of what our community members think about Regulus Therapeutics and other stocks. Vote "Outperform" if you believe RGLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
